07:05 EST Krystal Biotech (KRYS) sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech reports Q4 EPS $1.70, consensus $1.61
- Krystal Biotech, Inc. (KRYS) Q4 Earnings Cheat Sheet
- Krystal Biotech granted RMAT designation for KB707 in NSCLC
- Krystal Biotech price target raised to $327 from $206 at Goldman Sachs
- Krystal Biotech price target raised to $338 from $288 at Clear Street